• shutterstock_1151765522_slideshow_accelero.jpg

Accelero Bioanalytics GmbH (“Accelero”) announced key figures for the fiscal year 2020 in Germany´s Federal Gazette.


Berlin, 13 April 2021

In the light of the global financial crisis triggered by the SARS-CoV-2 pandemic, turnover nevertheless went up by 9% (Previous year 2019: 72%). Sales revenues remain constant with 3% (Previous year 2019: 4%). Approx. 70% of the years´s turnover is created by clients outside Germany.

Accelero currently experiences an extraordinary service order increase. 2021 first quarter results went up by 89% in comparison to the same period last year (Previous year 2020: 0%). Q1 2021 sales revenues accumulated to 14.7%.

The forecast has therefore been raised for the current year 2021. Accelero expects to continue creating high turnover throughout the year, resulting in an overall 30% turnover increase with approx. 12% sales revenues by the end of 2021. An outstanding feature is a contractual agreement covering the GLP-compliant development of a virus-based next generation COVID 19 vaccine.


Please click hereto download the press release.


Cookies user preferences
We use cookies to ensure you to get the best experience on our website. If you decline the use of cookies, this website may not function as expected.
Accept all
Decline all
Read more
Tools used to analyze the data to measure the effectiveness of a website and to understand how it works.
Google Analytics